The epidermal growth factor receptor family in breast cancer

References

• AlbainKElledgeRGradisharWJ2002Open-label, phase II, multicenter trial of ZD1839 (‘Iressa’) in patients with advanced breast cancerBreast Cancer Res Treat76Suppl 1A20
   Google Scholar
• AlimandiMRomanoACuriaMC1995Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomasOncogene101813217538656
   PubMed Web of Science ®Google Scholar
• AllredDCClarkGMTandonAK1992Her-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinomaJ Clin Oncol105996051548522
   PubMed Web of Science ®Google Scholar
• AnidoJScaltritiMBech SerraJJ2006Biosynthesis of tumorigenic HER-2 C-terminal fragments by alternative initiation of translationEMBO J2532344416794579
   PubMed Web of Science ®Google Scholar
• ArnouldLFargeotPBonneterreJ2003Epirubicin dose response effect in node positive breast cancer patients is independent of HER2 overexpression: 10-year retrospective analysis of French Adjuvant Study Group 05 trialBreast Cancer Res Treat76A538
   Google Scholar
• AubeleMAuerGWalchAK2007PTK (protein tyrosine kinase)- 6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomasBr J Cancer96801717299391
   PubMed Web of Science ®Google Scholar
• AustinCDDe MaziereAMPisacanePI2004Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinMol Biol Cell1552688215385631
   PubMed Web of Science ®Google Scholar
• BarnesNLKhavariSBolandGP2005Absence of HER-4 expression predicts recurrence of ductal carcinoma in situ of the breastClin Cancer Res112163815788662
   PubMed Web of Science ®Google Scholar
• BartlettJMallonECookeT2003The clinical evaluation of HER-2 status: which test to use?J Pathol1994111712635130
   PubMed Web of Science ®Google Scholar
• BaselgaJAlbanellJRuizA2005bPhase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancerJ Clin Oncol2353233315939921
   PubMed Web of Science ®Google Scholar
• BaselgaJCarbonellXCastaneda-SotoNJ2005aPhase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly scheduleJ Clin Oncol2321627115800309
   PubMed Web of Science ®Google Scholar
• BenderLMNahtaR2008Her2 cross talk and therapeutic resistance in breast cancerFront Biosci1339061218508484
   PubMed Web of Science ®Google Scholar
• BenöhrPHenkelVSpeerR2005Her-2/neu expression in breast cancer – A comparison of different diagnostic methodsAnticancer Res25189590016158923
   PubMed Web of Science ®Google Scholar
• BergqvistJOhdJFSmedsJ2007Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcomeAnn Oncol188455017351254
   PubMed Web of Science ®Google Scholar
• BiecheIOnodyPLaurendeauI1999Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applicationsClin Chem4511485610430778
   PubMed Web of Science ®Google Scholar
• BiecheIOnodyPTozluS2003Prognostic value of ERBB family mRNA expression in breast carcinomasInt J Cancer1067586512866037
   PubMed Web of Science ®Google Scholar
• BilanciaDRosatiGDinotaA2007Lapatinib in breast cancerAnn Oncol182630
   Web of Science ®Google Scholar
• BlackwellKKaplanEFrancoS2004A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer [abstract]Proc Am Soc Clin Oncol223006
   Web of Science ®Google Scholar
• BloomK2005The distribution of EGFR mRNA expression in 247 breast carcinomas and its relationship to ER mRNA expression [abstract]San Antonio Breast Cancer Symposium3039
   Google Scholar
• BonneterreJRocheHKerbratP200310-Year update of benefit/risk ratio after adjuvant chemotherapy (CT) in node positive (N+), early breast cancer (EBC) patients (pts) [abstract]Proc Am Soc Clin Oncol2293
   Google Scholar
• BorgATandonAKSigurdssonH1990HER-2/neu amplification predicts poor survival in node-positive breast cancerCancer Res50432272114213
   PubMed Web of Science ®Google Scholar
• BossardCBiecheILe DoussalV2005Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinomaAnticancer Res2546798316334160
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMPressM2008A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Res Treat Epub ahead of print
   Web of Science ®Google Scholar
• ChanSKHillMEGullickWJ2006The role of the epidermal growth factor receptor in breast cancerJ Mammary Gland Biol Neoplasia1131116947082
   PubMed Web of Science ®Google Scholar
• ChazinVRKalekoMMillerAD1992Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptorOncogene71859661354348
   PubMed Web of Science ®Google Scholar
• ChoongLYLimSLohMC2007Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeuticsMol Cancer Ther628284217989321
   PubMed Web of Science ®Google Scholar
• ChristiansonTADohertyJKLinYJ1998NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancerCancer Res58512399823322
   PubMed Web of Science ®Google Scholar
• CitriASkariaKBYardenY2003The deaf and the dumb: The biology of ErbB-2 and ErbB-3Exp Cell Res284546512648465
   PubMed Web of Science ®Google Scholar
• ClarkGMMcGuireWL1991Follow-up study of HER-2/neu amplification in primary breast cancerCancer Res5194481988136
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLG2000Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNat Med6443610742152
   PubMed Web of Science ®Google Scholar
• CooleySBurnsLJRepkaT1999Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neuExp Hematol2715334110517495
   PubMed Web of Science ®Google Scholar
• De LaurentiisMCaputoFMassarelliE2001HER2 expression and anthracycline effect: results from the Naples GUN 3 randomized trial [abstract]Proc Am Soc Clin Oncol20133
   Google Scholar
• De PlacidoSPerroneFCarlomagnoC1995CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer: a single centre randomised clinical trial (Naples GUN-3 study)Br J Cancer71128377779724
   PubMed Web of Science ®Google Scholar
• DeFazioAChiewY-ESiniRL2000Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell linesInt J Cancer874879810918187
   PubMed Web of Science ®Google Scholar
• Del MastroLBruzziPVenturiniM2004HER2 expression and efficacy of dose-dense anthracycline containing adjuvant chemotherapy in early breast cancer patients [abstract]Proc Am Soc Clin Oncol22571
   Web of Science ®Google Scholar
• DelordJPAllalCCanalM2005Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinomaAnn Oncol1618899716219625
   PubMed Web of Science ®Google Scholar
• Di LeoAGancbergDLarsimontD2002HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracilClin Cancer Res811071612006526
   PubMed Web of Science ®Google Scholar
• Di LeoALarsimontDBeauduinM1999CMF or anthracycline-based adjuvant chemotherapy for node-positive breast cancer patients: 4-year results of a Belgian randomized clinical trial with predictive markers analysis [abstract]Proc Am Soc Clin Oncol1869
   Google Scholar
• Di LeoALarsimontDGancbergD2001Her-2 and topoisomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamideAnn Oncol121081911583189
   PubMed Web of Science ®Google Scholar
• Di LeoA2007The state of HER-2 statusAnn Oncol188131517488732
   PubMed Web of Science ®Google Scholar
• DiermeierSHorvathGKnuechel-ClarkeR2005Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activationExp Cell Res3046041915748904
   PubMed Web of Science ®Google Scholar
• DiGiovannaMPLermanMACoffeyRJ1998Active signaling by Neu in transgenic miceOncogene171877849778054
   PubMed Web of Science ®Google Scholar
• DiGiovannaMPSternDFEdgertonSM2005Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patientsJ Clin Oncol2311526015718311
   PubMed Web of Science ®Google Scholar
• DittadiRDonisiPMBrazzaleA1993Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissueBr J Cancer67798427782
   PubMed Web of Science ®Google Scholar
• DowsettMBartlettJEllisIO2003Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centresJ Pathol1994182312635131
   PubMed Web of Science ®Google Scholar
• DowsettMCookeTEllisI2000Assessment of HER2 status in breast cancer: why, when, and how?Eur J Cancer36170610741274
   PubMed Web of Science ®Google Scholar
• DresslerLGBerryDABroadwaterG2005Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patientsJ Clin Oncol2342879715994142
   PubMed Web of Science ®Google Scholar
• ECOG E11002003A phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2)Clin Adv Hematol Oncol123716224413
   PubMedGoogle Scholar
• EllisIOBartlettJDowsettM2004Best practice No 176: updated recommendations for HER2 testing in the UKJ Clin Pathol57233714990588
   PubMed Web of Science ®Google Scholar
• EstevaFJSahinAACristofanilliM2005Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapyClin Cancer Res1133151915867229
   PubMed Web of Science ®Google Scholar
• FerreroJMRamaioliALargillierR2001Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-upAnn Oncol12841611484962
   PubMed Web of Science ®Google Scholar
• FountzilasGPectasidesDKalogera-FountzilaA2005Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology GroupBreast Cancer Res Treat921915980985
   PubMed Web of Science ®Google Scholar
• FoxSBSmithKHollyerJ1994The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patientsBreast Cancer Res Treat294198018963
   PubMed Web of Science ®Google Scholar
• GaspariniGGullickWJMalutaS1994C-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma. An immunocytochemical studyEur J Cancer30A16227908213
   PubMed Web of Science ®Google Scholar
• GennariASormaniMPPronzatoP2008HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trialsJ Natl Cancer Inst100142018159072
   PubMed Web of Science ®Google Scholar
• GennariRMenardSFagnoniF2004Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2Clin Cancer Res105650515355889
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistD2006Lapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med35527334317192538
   PubMed Web of Science ®Google Scholar
• GinestierCCharafe-JauffretEPenault-LlorcaF2004Comparative multi-methodological measurement of ERBB2 status in breast cancerJ Pathol2022869814991893
   PubMed Web of Science ®Google Scholar
• GjerdrumLMSorensenBSKjeldsenE2004Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysisJ Mol Diagn6425114736826
   PubMed Web of Science ®Google Scholar
• GomezHChavezMDovalD2005A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer [abstract]Proc Am Soc Clin Oncol233046
   Google Scholar
• Gonzalez-AnguloAMKrishnamurthySYamamuraY2004Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinomaCancer1012586315241821
   PubMed Web of Science ®Google Scholar
• Graus-PortaDBeerliRRDalyJM1997ErbB-2, the preferred heterodimerization partner of all HER receptors, is a mediator of lateral signalingEMBO J161647559130710
   PubMed Web of Science ®Google Scholar
• GullickWJSrinivasanR1998The type I growth factor receptor family: new ligands and receptors and their role in breast cancerBreast Cancer Res Treat52435310066071
   PubMed Web of Science ®Google Scholar
• GustersonBAGelberRDGoldhirschA1992Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study GroupJ Clin Oncol101049561351538
   PubMed Web of Science ®Google Scholar
• HarrisRCChungECoffeyRJ2003EGF receptor ligandsExp Cell Res28421312648462
   PubMed Web of Science ®Google Scholar
• HartmannLCIngleJNWoldLE1994Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocolCancer742956637954259
   PubMed Web of Science ®Google Scholar
• HayesDFThorADDresslerLG2007Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancerN Engl J Med357149650617928597
   PubMed Web of Science ®Google Scholar
• HolbroTBeerliRRMaurerF2003The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationProc Natl Acad Sci U S A1008933812853564
   PubMed Web of Science ®Google Scholar
• HsiehACMoasserMM2007Targeting HER proteins in cancer therapy and the role of the non-target HER3Br J Cancer97453717667926
   PubMed Web of Science ®Google Scholar
• IsolaJTannerMForsythA2004Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridizationClin Cancer Res104793815269154
   PubMed Web of Science ®Google Scholar
• IzumiYXuLDiTE2002Tumour biology: herceptin acts as an anti-angiogenic cocktailNature4162798011907566
   PubMed Web of Science ®Google Scholar
• JacobsTWGownAMYazijiH1999Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancerJ Clin Oncol1719748210561247
   PubMed Web of Science ®Google Scholar
• JannotCBBeerliRRMasonS1996Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cellsOncogene13275828710366
   PubMed Web of Science ®Google Scholar
• JoensuuHKellokumpu-LehtinenPLBonoP2006Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerN Engl J Med3548092016495393
   PubMed Web of Science ®Google Scholar
• KainulainenVSundvallMMäättäJA2000A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxisJ Biol Chem2758641910722704
   PubMed Web of Science ®Google Scholar
• KaramouzisMVBadraFAPapavassiliouAG2007Breast cancer: The upgraded role of HER-3 and HER-4Int J Biochem Cell Biol39851617254832
   PubMed Web of Science ®Google Scholar
• KaurHSilvermanPSinghD2006Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC)J Clin Oncol24Suppl 1810623
   Google Scholar
• KewTYBellJAPinderSE2000C-erbB-4 protein expression in human breast cancerBr J Cancer8211637010735500
   PubMed Web of Science ®Google Scholar
• KimYRChoiJRSongKS2002Evaluation of HER2/neu status by real-time quantitative PCR in breast cancerYonsei Med J433354012089741
   PubMed Web of Science ®Google Scholar
• KirkegaardTMcGlynnLMCampbellFM2007Amplified in breast cancer 1 in human epidermal growth factor receptor – positive tumours of tamoxifen-treated breast cancer patientsClin Cancer Res1314051117332282
   PubMed Web of Science ®Google Scholar
• KjeldsenEK⊘lvraaSRautenstraussBLiehrT2002FISH techniques, FISH probes and their applications in medicine and biology: an overviewFISH TechnologyBerlinSpringer350
   Google Scholar
• KlijnJGBernsPMSchmitzPI1992The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patientsEndocr Rev133171313356
   PubMed Web of Science ®Google Scholar
• KlosKSZhouXLeeS2003Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment aloneCancer9813778514508823
   PubMed Web of Science ®Google Scholar
• KnowldenJMGeeJMWSeeryLT1998c-erbB-3 and c-erbB-4 expression is a feature of the endocrine responsive phenotype in clinical breast cancerOncogene171949579788438
   PubMed Web of Science ®Google Scholar
• KnowldenJMHutchesonIRJonesHE2003Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen resistant MCF-7 cellsEndocrinology14410324412586780
   PubMed Web of Science ®Google Scholar
• KokaiYMyersJNWadaT1989Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblastsCell58287922568888
   PubMed Web of Science ®Google Scholar
• KonecnyGEThomssenCLuckHJ2004Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancerJ Natl Cancer Inst9611415115292386
   PubMedGoogle Scholar
• KönigshoffMWilhelmJBohleRM2003HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissueClin Chem492192912560343
   PubMed Web of Science ®Google Scholar
• KostopoulosIArapantoni-DadiotiPGogasH2006Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose–dense sequential adjuvant chemotherapyBreast Cancer Res Treat962516116538542
   PubMed Web of Science ®Google Scholar
• KrauseDSVan EttenRA2005Tyrosine kinases as targets for cancer therapyN Engl J Med3531728716014887
   PubMed Web of Science ®Google Scholar
• KulkaJTôkésAMKaposi-NovákP2006Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR – A comparison with immunohistochemical and FISH resultsPathol Oncol Res1219720417189981
   PubMed Web of Science ®Google Scholar
• LaaksoMTannerMIsolaJ2006Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumoursJ Pathol2103916823892
   PubMed Web of Science ®Google Scholar
• LabuhnMVuaroqueauxVFinaF2006Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCRInt J Biol Markers2130916711511
   PubMed Web of Science ®Google Scholar
• LaneHAMotoyamaABBeuvinkI2001Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signalingAnn Oncol12Suppl 1S21S2211521716
   PubMed Web of Science ®Google Scholar
• LebeauAUnholzerAAmannG2003EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breastBreast Cancer Res Treat791879812825853
   PubMed Web of Science ®Google Scholar
• LeeHAkitaRWSliwkowskiMX2001A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4Cancer Res6144677311389077
   PubMed Web of Science ®Google Scholar
• LeeYChoSSeoJH2007Correlated expression of erbB-3 with hormone receptor expression and favourable clinical outcome in invasive ductal carcinomas of the breastAm J Clin Pathol1281041918024331
   PubMed Web of Science ®Google Scholar
• LemoineNRBarnesDMHollywoodDP1992Expression of the ERBB3 gene product in breast cancerBr J Cancer661116211333787
   PubMed Web of Science ®Google Scholar
• LewisGDFigariIFendlyB1993Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodiesCancer Immunol Immunother37255638102322
   PubMed Web of Science ®Google Scholar
• LiuBOrdonez-ErcanDFanZ2007Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cellsInt J Cancer12018748217266042
   PubMed Web of Science ®Google Scholar
• LuYZiXZhaoY2001Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst931852711752009
   PubMed Web of Science ®Google Scholar
• MansourEGGrayRShatilaAH1989Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an intergroup studyN Engl J Med320485902915651
   PubMed Web of Science ®Google Scholar
• MarcomPKIsaacsCHarrisL2007The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancersBreast Cancer Res Treat10243916897431
   PubMed Web of Science ®Google Scholar
• MarsiglianteSMuscellaACiardoV1993Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic gradesCancer Lett751952067906196
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiD2005Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol2342657415911866
   PubMed Web of Science ®Google Scholar
• MassR2000The role of HER-2 expression in predicting response to therapy in breast cancerSemin Oncol27465211236028
   PubMed Web of Science ®Google Scholar
• MassarwehSOsborneCKCreightonCJ2008Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionCancer Res688263318245484
   PubMed Web of Science ®Google Scholar
• MasudaNOhnishiTKawamotoS1999Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samplesNucleic Acids Res2744364310536153
   PubMed Web of Science ®Google Scholar
• MitchellMSPressMF1999The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancerSemin Oncol261081610482202
   PubMed Web of Science ®Google Scholar
• MoasserMM2007The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene2664698717471238
   PubMed Web of Science ®Google Scholar
• MolinaMACodony-ServatJAlbanellJ2001Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cellsCancer Res614744911406546
   PubMed Web of Science ®Google Scholar
• MolinaMASaezRRamseyEE2002NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancerClin Cancer Res83475311839648
   PubMed Web of Science ®Google Scholar
• MoliterniAMenardSValagussaP2003HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancerJ Clin Oncol214586212560435
   PubMed Web of Science ®Google Scholar
• MosessonYYardenY2004Oncogenic growth factor receptors: Implications for signal transduction therapySemin Cancer Biol142627015219619
   PubMed Web of Science ®Google Scholar
• MrhalovaMKodetRKalinovaM2003Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB2 protein expression and ERBB2 gene copy numberPathol Res Pract1994536114521261
   PubMed Web of Science ®Google Scholar
• MullerWJArteagaCLMuthuswamySK1996Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic miceMol Cell Biol165726368816486
   PubMed Web of Science ®Google Scholar
• MusolinoANaldiNBortesiB2008Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancerJ Clin Oncol2617899618347005
   PubMed Web of Science ®Google Scholar
• MussHBThorADBerryDA1994c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerN Engl J Med330126067908410
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouX2004PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell61172715324695
   PubMed Web of Science ®Google Scholar
• NagyPFriedlanderETannerM2005Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell lineCancer Res654738215695389
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJ2007Trastuzumab: triumphs and tribulationsOncogene2636374317530017
   PubMed Web of Science ®Google Scholar
• NaiduRYadavMNairS1998Expression of c-erbB3 protein in primary breast carcinomasBr J Cancer781385909823984
   PubMed Web of Science ®Google Scholar
• NareshALongWVidalGA2006The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cellsCancer Res6664122016778220
   PubMed Web of Science ®Google Scholar
• NeveRMSutterlutyHPullenN2000Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cellsOncogene1916475610763821
   PubMed Web of Science ®Google Scholar
• NicholsonRIGeeJMHarperME2001EGFR and breast cancer prognosisEur J Cancer3791511165124
   PubMed Web of Science ®Google Scholar
• NicholsonRIHutchesonIRHarperME2002Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancerAnn N Y Acad Sci96310415
   Web of Science ®Google Scholar
• NicholsonRIHutchesonIRKnowldenJM2004Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combinationClin Cancer Res101 Pt 2346S54S14734490
   PubMed Web of Science ®Google Scholar
• NtouliaMKaklamanisLValavanisC2006HER-2 DNA quantification of paraffin-embedded breast carcinomas with Light Cycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridizationClin Biochem39942616916505
   PubMed Web of Science ®Google Scholar
• O’MalleyFPParkesRLattaE2001Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistryAm J Clin Pathol1155041111293897
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJWecksteinDJVukeljaSJ2007Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancerBreast Cancer Res Treat106Suppl 1S32
   Google Scholar
• PaikSBryantJParkC1998erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancerJ Natl Cancer Inst901361709747867
   PubMed Web of Science ®Google Scholar
• PaikSBryantJTan-ChiuE2000HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15J Natl Cancer Inst921991811121461
   PubMedGoogle Scholar
• PaikSBryantJTan-ChiuE2002Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experienceJ Natl Cancer Inst94852412048273
   PubMed Web of Science ®Google Scholar
• PatersonMCDietrichKDDanylukJ1991Correlation between c-erb-2 amplification and risk of recurrent disease in node-negative breast cancerCancer Res515667
   Web of Science ®Google Scholar
• PawlowskiVRevillionFHebbarM2000Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assayClin Cancer Res642172511106235
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNE2006HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trialJ Clin Oncol243032816809727
   PubMed Web of Science ®Google Scholar
• PetitTBorelCGhnassiaJP2001Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant settingClin Cancer Res715778111410493
   PubMed Web of Science ®Google Scholar
• PetrelliFCabidduMCazzanigaME2008Targeted therapies for the treatment of breast cancer in the post-trastuzumab eraOncologist133738118448551
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesB2005Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med35316597216236737
   PubMed Web of Science ®Google Scholar
• PietrasRJArboledaJReeseDM1995HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cellsOncogene102435467784095
   PubMed Web of Science ®Google Scholar
• PotemskiPPluciennikEBednarekAK2006A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistryMed Sci Monit125761
   Web of Science ®Google Scholar
• PressMFHungGGodolphinW1994Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expressionCancer Res54277177909495
   PubMed Web of Science ®Google Scholar
• PrigentSAGullickWJ1994Identification of c-erbB-3 binding sites for phosphatidylinositol 3’-kinase and SHC using an EGF receptor/c-erbB-3 chimeraEMBO J132831418026468
   PubMed Web of Science ®Google Scholar
• PritchardKIShepherdLEO’MalleyFP2006HER2 and responsiveness of breast cancer to adjuvant chemotherapyN Engl J Med35421031116707747
   PubMed Web of Science ®Google Scholar
• QuenelNWafflartJBonichonF1995The prognostic value of c-erbB-2 in primary breast carcinomas: a study on 942 casesBreast Cancer Res Treat35283917579499
   PubMed Web of Science ®Google Scholar
• QuinnCMOstrowskiJLLaneSA1994C-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survivalHistopathology25247527821892
   PubMed Web of Science ®Google Scholar
• RampaulRSPinderSENicholsonRI2005Clinical value of epidermal growth factor receptor expression in primary breast cancerAdv Anat Pathol12271316210923
   PubMed Web of Science ®Google Scholar
• RampaulRSPinderSEWencykPM2004Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?Clin Cancer Res10257815073139
   PubMed Web of Science ®Google Scholar
• RavdinPMGreenSAlbainK1998Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone [abstract]Proc Am Soc Clin Oncol1797
   Google Scholar
• RilkeFColnaghiMICascinelliN1991Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factorsInt J Cancer494491678734
   PubMed Web of Science ®Google Scholar
• RobertsonJGutteridgeECheungK2003Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study [abstract]Proc Am Soc Clin Oncol2223
   PubMed Web of Science ®Google Scholar
• RobertsonKWReevesJRSmithG1996Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancerCancer Res563823308706030
   PubMed Web of Science ®Google Scholar
• RochePCSumanVJJenkinsRB2002Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831J Natl Cancer Inst94855712048274
   PubMedGoogle Scholar
• RodenhuisSBontenbalMBeexL2003High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancerN Engl J Med34971612840087
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJ2005Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med35316738416236738
   PubMed Web of Science ®Google Scholar
• RossJSFletcherJA1998The Her-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapyStem Cells16413289831867
   PubMed Web of Science ®Google Scholar
• RoyVPerezEA2006New therapies in the treatment of breast cancerSemin Oncol3338
   Web of Science ®Google Scholar
• SartorCIZhouHKozlowskaE2001Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cellsMol Cell Biol2142657511390655
   PubMed Web of Science ®Google Scholar
• SassenARochonJWildPJ2008Cytogenetic analysis of HER1/EGFR, HER2, HER3, AND HER4 in 278 breast cancer patientsBreast Cancer Res10R218182100
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcañaA2007Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst996283817440164
   PubMed Web of Science ®Google Scholar
• SchiffRMassarwehSAShouJ2005Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulatorsCancer Chemother Pharmacol56102016273359
   PubMed Web of Science ®Google Scholar
• SchlemmerBOSorensenBSOvergaardJ2004Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with Light Cycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridizationScand J Clin Lab Invest645112215276916
   PubMed Web of Science ®Google Scholar
• SerginaNVRauschMWangD2007Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature4454374117206155
   PubMed Web of Science ®Google Scholar
• ShouJMassarwehSOsborneCK2004Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJ Natl Cancer Inst969263515199112
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertN2005Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 studyBreast Cancer Res Treat94Suppl 1S5
   Google Scholar
• SlamonDJClarkGMWongSG1987Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience235177823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLA1989Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience244707122470152
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakS2001Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med3447839211248153
   PubMed Web of Science ®Google Scholar
• SmithIProcterMGelberRD20072-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialLancet3699555293617208639
   PubMed Web of Science ®Google Scholar
• SoltoffSPCarrawayKL3rdPrigentSA1994ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factorMol Cell Biol14355087515147
   PubMed Web of Science ®Google Scholar
• SrinivasanRPoulsomRHurstHC1998Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour typesJ Pathol185236459771476
   PubMed Web of Science ®Google Scholar
• SuoZDaehliKULindboeCF2004Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patientsInt J Surg Pathol123111815494857
   PubMed Web of Science ®Google Scholar
• SuoZRisbergBKalssonMG2002EGFR family expression in breast carcinomas. C-erbB-2 and c-erbB-4 receptors have different effects on survivalJ Pathol196172511748637
   PubMed Web of Science ®Google Scholar
• TangCKConcepcionXZMilanM1999Ribozyme-mediated downregulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivoCancer Res5953152210537315
   PubMed Web of Science ®Google Scholar
• [TLBC] The Ludwig Breast Cancer Study Group1988Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycleN Engl J Med319677832901037
   PubMed Web of Science ®Google Scholar
• [TLBC] The Ludwig Breast Cancer Study Group1989Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancerN Engl J Med32049162644533
   PubMed Web of Science ®Google Scholar
• ThomsonTAHayesMMSpinelliJJ2001HER-2/neu in breast cancer: inter-observer variability and performance of immunohistochemistry with four antibodies compared with fluorescent in situ hybridizationMod Pathol1410798611706067
   PubMed Web of Science ®Google Scholar
• ThorADBerryDABudmanDR1998erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancerJ Natl Cancer Inst901346609747866
   PubMed Web of Science ®Google Scholar
• ToikkanenSHelinHIsolaJ1992Prognostic significance of Her-2 oncoprotein expression in breast cancer: a 30-year follow-upJ Clin Oncol10104481351537
   PubMed Web of Science ®Google Scholar
• ToveySDunneBWittonCJ2005Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?Clin Cancer Res1148354216000581
   PubMed Web of Science ®Google Scholar
• TravisAPinderSERobertsonJFR1996C-erbB-3 in human breast carcinoma : expression and relation to prognosis and established prognostic indicatorsBr J Cancer74229338688326
   PubMed Web of Science ®Google Scholar
• TseCBraultDGligorovJ2005Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patientsClin Chem51109310115976096
   PubMed Web of Science ®Google Scholar
• TsutsuiSOhnoSMurakamiS2002Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancerBreast Cancer Res Treat71677511859875
   PubMed Web of Science ®Google Scholar
• UedaSTsudaHSatoK2005Differential overexpressions of EGFR, c-erbB-2, and IGF1R in histological types, nuclear grades, and hormone receptors status of breast carcinoma [abstract]San Antonio Breast Cancer Symposium5114
   Google Scholar
• Ursini-SiegelJSchadeBCardiffRD2007Insights from transgenic mouse models of ERBB2-induced breast cancerNat Rev Cancer73899717446858
   PubMed Web of Science ®Google Scholar
• ValabregaGMontemurroFAgliettaM2007Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancerAnn Oncol189778417229773
   PubMed Web of Science ®Google Scholar
• ValabregaGMontemurroFSarottoI2005TGFalpha expression impairs trastuzumab-induced HER2 downregulationOncogene2430021015735715
   PubMed Web of Science ®Google Scholar
• Vanden BemptIVanhentenrijkVDrijkoningenM2005Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomasHistopathology464314115810955
   PubMed Web of Science ®Google Scholar
• VinatzerUDampierBStreubelB2005Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridizationClin Cancer Res1183485716322295
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyD2002Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol207192611821453
   PubMed Web of Science ®Google Scholar
• von MinckwitzGJonatWFaschingP2005A multicentre phase II study on gefitinib in taxane-and anthracycline-pretreated metastatic breast cancerBreast Cancer Res Treat891657215692759
   PubMed Web of Science ®Google Scholar
• WalkerRADearingSJ1999Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomasBreast Cancer Res Treat531677610326794
   PubMed Web of Science ®Google Scholar
• WinstanleyJCookeTMurrayGD1991The long term prognostic significance of c-erb-2 in primary breast cancerBr J Cancer63447501672256
   PubMed Web of Science ®Google Scholar
• WittonCJReevesJRGoingJJ2003Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerJ Pathol200290712845624
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJN2007American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol251184517159189
   PubMed Web of Science ®Google Scholar
• WoodWCBudmanDRKorzunAH1994Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinomaN Engl J Med330125398080512
   PubMed Web of Science ®Google Scholar
• YangZBarnesCJKumarR2004Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cellsClin Cancer Res103621815173068
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMX2001Untangling the ErbB signalling networkNat Rev Mol Cell Biol21273711252954
   PubMed Web of Science ®Google Scholar
• ZabreckyJRLamTMcKenzieSJ1991The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, sk-br-3J Biol Chem2661716201671042
   PubMed Web of Science ®Google Scholar
• ZaczekAWełnicka-JaśekiewiczMBielawskiKP2008Gene copy numbers of HER family in breast cancerJ Cancer Res Clin Oncol134271917661082
   PubMed Web of Science ®Google Scholar
• ZhangFYangYSmithT2003Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinomaCancer9717586512655533
   PubMed Web of Science ®Google Scholar